Therapeutically targeting the sonic hedgehog (shh) signaling pathway for the treatment of acute myeloid leukemia (AML) is an exciting area, with Smoothened (SMO) inhibitors already used successfully in the treatment of skin cancer. Here, Jorge Cortes, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the data from his presentation on the SMO inhibitor glasdegib for AML at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL. Prof. Cortes discusses the more recent and very promising data from combination regimens of glasdegib, including BRIGHT AML1019 (NCT03416179). He then gives his perspective on potential combinations with other novel agents.
Smoothening the spines: hedgehog signaling inhibitor glasdegib combinations for AML
